Combined treatment with cognitive-behavioural therapy in adolescent depression: Meta-analysis

British Journal of Psychiatry

Volumn 197, Issue 6, 2010, Pages 433-440

  Dubicka, Bernadka ^a   Elvins, Rachel ^a   Roberts, Chris ^a   Chick, Greg ^b   Wilkinson, Paul ^c   Goodyer, Ian M ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT DEPRESSION; ADOLESCENT DISEASE; ARTICLE; AUTOMUTILATION; CLINICAL TRIAL; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; DRUG INDUCED HEADACHE; FATIGUE; FOLLOW UP; HUMAN; HYPOMANIA; INSOMNIA; IRRITABILITY; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOTHERAPY; SEDATION; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 78649663804     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.109.075853     Document Type: Article

References (27)

1. Committee on Safety in Medicines. Use of Selective Serotonin Reuptake Inhibitors (SSRIs) in Children and Adolescents with Major Depressive Disorder (MDD). Committee on Safety in Medicines, 2003.
2. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull 2006; 132: 132-49.
3. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA 2004; 292: 807-20.
4. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression. Arch Gen Psychiatry 2004; 61: 714-9.
5. Harrington R, Whittaker J, Shoebridge P, Campbell F. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. BMJ 1998; 316: 1559-63.
6. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; 2: CD002317.
7. Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNulty S, et al. Treatment for adolescents with depression study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006; 45: 1440-55.
8. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
9. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I2 in assessing heterogeneity may mislead. BMC Medical Res Methodology 2008; 8: 79.
10. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-analysis in Medical Research. John Wiley, 2000.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
12. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299: 901-13.
13. Clarke G, Debar L, Lynch F, Powell J, Gale J, O'Connor E, et al. A randomised effectiveness trial of brief cognitive-behavioural therapy for depressed adolescents receiving antidepressant medication. J Am Acad Child Adolesc Psychiatry 2005; 44: 888-98.
14. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335: 142-6.
15. Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit E. A comparison of cognitive-behavioural therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 2006; 10: 1151-61.
16. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64: 1132-43.
17. Clarke GN, Hornbrook M, Lynch F, Polen M, Gale J, O'Connor E, et al. Group cognitive-behavioural treatment for depressed adolescent parents in a health maintenance organisation. J Am Acad Child Adolesc Psychiatry 2002; 41: 305-13.
18. Curry J, Rodhe P, Simons A, Silva S, Vitiello B, Kratochvil C, et al. Predictors and moderators of acute outcome in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45: 1427-38.
19. Brent DA, Kolko DJ, Birmaher B, Baugher M, Bridge J, Roth C, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 1998; 37: 906-14.
20. Treatment for Adolescents With Depression Study Team. Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003; 42: 531-42.
21. Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess 2008; 12: ix-60.
22. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito H, Ritz L, et al. Preditors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009; 166: 418-26.
23. Vitiello B, Rohde P, Silva SG, Wells KC, Casat C, Waslick BD, et al. Effects of treatment on level of functioning, global health, and quality of life in depressed adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 1419-26.
24. Byford S, Barrett B, Roberts C, Wilkinson P, Dubicka B, Kelvin RG, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive-behavioural therapy in adolescents with major depression. Br J Psychiatry 2007; 191: 521-7.
25. Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, et al. Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry 2008; 165: 588-96.
26. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, et al. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 711-20.
27. Kennard BD, Silva SG, Mayes TL, Rohde P, Hughes JL, Vitiello B, et al. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry 2009; 166: 337-44.